Clinical studies have validated the enrichment of exosomal circUSP7 in NSCLC samples and upregulated USP7 predicts unfavorable outcomes and CD8+ T cell dysfunction, suggesting that it might be adopted in clinical arena to harness its clinical potential (39). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.